Jon C Aster

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3333148/publications.pdf

Version: 2024-02-01

216 papers	37,404 citations	2538 96 h-index	3094 187 g-index
221 all docs	221 docs citations	221 times ranked	38401 citing authors

#	Article	IF	Citations
1	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science, 2004, 306, 269-271.	6.0	2,494
2	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 2002, 8, 68-74.	15.2	2,217
3	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	13.7	2,112
4	Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination. Immunity, 1999, 11, 299-308.	6.6	853
5	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	13.9	810
6	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 2003, 102, 3871-3879.	0.6	793
7	c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes and Development, 2006, 20, 2096-2109.	2.7	782
8	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	0.6	778
9	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18261-18266.	3.3	745
10	Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462, 182-188.	13.7	712
11	Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 2019, 176, 1265-1281.e24.	13.5	642
12	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254.	1.8	626
13	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 2011, 471, 104-109.	13.7	558
14	The Varied Roles of Notch in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 245-275.	9.6	511
15	MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors. Nature Genetics, 2000, 26, 484-489.	9.4	506
16	Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine, 2002, 8, 979-986.	15.2	506
17	Myc-Induced T Cell Leukemia in Transgenic Zebrafish. Science, 2003, 299, 887-890.	6.0	506
18	Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nature Biotechnology, 2014, 32, 941-946.	9.4	477

#	Article	IF	Citations
19	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	3.3	405
20	Structural Basis for Cooperativity in Recruitment of MAML Coactivators to Notch Transcription Complexes. Cell, 2006, 124, 973-983.	13.5	390
21	Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell, 2017, 20, 233-246.e7.	5.2	387
22	Molecular Biology of Burkittâ€™s Lymphoma. Journal of Clinical Oncology, 2000, 18, 3707-3721.	0.8	386
23	Inhibition of DNA replication factor RPA by p53. Nature, 1993, 365, 79-82.	13.7	373
24	Calcium Depletion Dissociates and Activates Heterodimeric Notch Receptors. Molecular and Cellular Biology, 2000, 20, 1825-1835.	1.1	368
25	Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody. American Journal of Surgical Pathology, 2009, 33, 984-991.	2.1	364
26	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
27	Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling. Molecular and Cellular Biology, 2003, 23, 655-664.	1.1	341
28	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
29	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature Genetics, 2014, 46, 364-370.	9.4	333
30	F3/Contactin Acts as a Functional Ligand for Notch during Oligodendrocyte Maturation. Cell, 2003, 115, 163-175.	13.5	332
31	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. Journal of Experimental Medicine, 2006, 203, 311-317.	4.2	326
32	Notch signaling controls the generation and differentiation of early T lineage progenitors. Nature Immunology, 2005, 6, 663-670.	7.0	320
33	Structural basis for autoinhibition of Notch. Nature Structural and Molecular Biology, 2007, 14, 295-300.	3.6	317
34	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	3.3	314
35	Notch Signaling in Cancer. Cancer Biology and Therapy, 2002, 1, 466-476.	1.5	311
36	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.4	310

#	Article	IF	Citations
37	FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics, 1998, 18, 84-87.	9.4	301
38	Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2939-48.	3.3	292
39	Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2. Molecular Cell, 2000, 6, 693-704.	4.5	289
40	Mechanical Allostery: Evidence for a Force Requirement in the Proteolytic Activation of Notch. Developmental Cell, 2015, 33, 729-736.	3.1	288
41	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. Journal of Investigative Dermatology, 2014, 134, 2630-2638.	0.3	287
42	The multifaceted role of Notch in cancer. Current Opinion in Genetics and Development, 2007, 17, 52-59.	1.5	271
43	Canonical Notch Signaling Is Dispensable for theÂMaintenance of Adult Hematopoietic Stem Cells. Cell Stem Cell, 2008, 2, 356-366.	5.2	271
44	Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood, 2004, 104, 1696-1702.	0.6	265
45	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood, 2007, 110, 278-286.	0.6	263
46	Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of T-Cell Leukemia by Notch1. Molecular and Cellular Biology, 2000, 20, 7505-7515.	1.1	255
47	Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO Journal, 1998, 17, 5321-5333.	3.5	249
48	Leukemia-Associated Mutations within the NOTCH1 Heterodimerization Domain Fall into at Least Two Distinct Mechanistic Classes. Molecular and Cellular Biology, 2006, 26, 4642-4651.	1.1	241
49	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	7.7	240
50	Notch Signaling in Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 587-613.	9.6	237
51	Deltex1 Redirects Lymphoid Progenitors to the B Cell Lineage by Antagonizing Notch1. Immunity, 2002, 16, 231-243.	6.6	235
52	Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2007, 25, 1741-1746.	0.8	235
53	Tribbles homolog 2 inactivates C/EBPÎ± and causes acute myelogenous leukemia. Cancer Cell, 2006, 10, 401-411.	7.7	232
54	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227

#	Article	IF	Citations
55	Activity of the PI3K-Î´,Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood, 2018, 131, 888-898.	0.6	224
56	Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14908-14913.	3.3	221
57	NOTCH1â€“RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 705-710.	3.3	218
58	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nature Genetics, 2016, 48, 265-272.	9.4	216
59	Activating Notch1 mutations in mouse models of T-ALL. Blood, 2006, 107, 781-785.	0.6	215
60	NUT Rearrangement in Undifferentiated Carcinomas of the Upper Aerodigestive Tract. American Journal of Surgical Pathology, 2008, 32, 828-834.	2.1	201
61	Multiple niches for Notch in cancer: context is everything. Current Opinion in Genetics and Development, 2004, 14, 48-54.	1.5	198
62	Delta-Like 4 Induces Notch Signaling in Macrophages. Circulation, 2007, 115, 2948-2956.	1.6	196
63	Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-rasâ€“initiated leukemia. Journal of Clinical Investigation, 2008, 118, 3181-3194.	3.9	194
64	BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19). American Journal of Pathology, 2001, 159, 1987-1992.	1.9	188
65	Notch Subunit Heterodimerization and Prevention of Ligand-Independent Proteolytic Activation Depend, Respectively, on a Novel Domain and the LNR Repeats. Molecular and Cellular Biology, 2004, 24, 9265-9273.	1.1	186
66	Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood, 2005, 106, 3898-3906.	0.6	186
67	T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20060-20065.	3.3	182
68	Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14902-14907.	3.3	180
69	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2014, 124, 644-655.	3.9	180
70	Structural Requirements for Assembly of the CSLÂ·Intracellular Notch1Â·Mastermind-like 1 Transcriptional Activation Complex. Journal of Biological Chemistry, 2003, 278, 21232-21239.	1.6	178
71	Modulation of Notch Signaling by Antibodies Specific for the Extracellular Negative Regulatory Region of NOTCH3. Journal of Biological Chemistry, 2008, 283, 8046-8054.	1.6	177
72	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood, 2009, 113, 1689-1698.	0.6	173

#	Article	IF	Citations
73	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 750-763.	7.7	173
74	Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient. New England Journal of Medicine, 1998, 339, 444-449.	13.9	169
75	Separation of Notch1 Promoted Lineage Commitment and Expansion/Transformation in Developing T Cells. Journal of Experimental Medicine, 2001, 194, 99-106.	4.2	165
76	Oncogenic Forms of NOTCH1 Lacking Either the Primary Binding Site for RBP-JÎº or Nuclear Localization Sequences Retain the Ability to Associate with RBP-JÎº and Activate Transcription. Journal of Biological Chemistry, 1997, 272, 11336-11343.	1.6	164
77	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discovery, 2017, 7, 156-164.	7.7	164
78	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene, 2014, 33, 1736-1742.	2.6	155
79	Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood, 2009, 113, 4381-4390.	0.6	154
80	Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors. PLoS ONE, 2010, 5, e9094.	1.1	154
81	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4946-53.	3.3	151
82	Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5012-5017.	3.3	149
83	Notch signalling in Tâ€cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. Journal of Pathology, 2011, 223, 263-274.	2.1	149
84	Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2103-2108.	3.3	145
85	Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. Journal of Molecular Diagnostics, 2016, 18, 507-515.	1.2	144
86	The double-edged sword of Notch signaling in cancer. Seminars in Cell and Developmental Biology, 2012, 23, 458-464.	2.3	137
87	Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer. Cancer Cell, 2013, 23, 390-405.	7.7	130
88	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242.	7.7	126
89	Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling. Circulation, 2019, 139, 78-96.	1.6	126
90	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	4.6	124

#	Article	IF	Citations
91	Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma. Cancer Discovery, 2014, 4, 1154-1167.	7.7	123
92	Cutaneous Î²-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1473-80.	3.3	119
93	Notch Signaling Specifies Megakaryocyte Development from Hematopoietic Stem Cells. Cell Stem Cell, 2008, 3, 314-326.	5.2	117
94	Structural and mechanistic insights into cooperative assembly of dimeric Notch transcription complexes. Nature Structural and Molecular Biology, 2010, 17, 1312-1317.	3.6	110
95	Intrinsic Selectivity of Notch 1 for Delta-like 4 Over Delta-like 1. Journal of Biological Chemistry, 2013, 288, 25477-25489.	1.6	110
96	The Role of Notch Receptors in Transcriptional Regulation. Journal of Cellular Physiology, 2015, 230, 982-988.	2.0	107
97	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood, 2018, 132, 1495-1506.	0.6	100
98	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS ONE, 2013, 8, e67306.	1.1	98
99	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols, 2019, 14, 2900-2930.	5.5	92
100	Effects of S1 Cleavage on the Structure, Surface Export, and Signaling Activity of Human Notch1 and Notch2. PLoS ONE, 2009, 4, e6613.	1.1	90
101	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood, 2018, 132, 935-947.	0.6	87
102	Identification of a Conserved Negative Regulatory Sequence That Influences the Leukemogenic Activity of NOTCH1. Molecular and Cellular Biology, 2006, 26, 6261-6271.	1.1	86
103	Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood, 2010, 116, 5455-5464.	0.6	86
104	Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques. Molecular Cell, 2019, 73, 1174-1190.e12.	4.5	83
105	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	5.8	80
106	Detection of BCL2 Rearrangements in Follicular Lymphoma. American Journal of Pathology, 2002, 160, 759-763.	1.9	76
107	Notch dimerization is required for leukemogenesis and T-cell development. Genes and Development, 2010, 24, 2395-2407.	2.7	76
108	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell, 2017, 21, 547-555.e8.	5.2	71

#	Article	IF	Citations
109	Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood, 2010, 116, 5443-5454.	0.6	68
110	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood, 2016, 127, 2203-2213.	0.6	68
111	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Reports, 2017, 21, 784-797.	2.9	65
112	Pharmacological disruption of the Notch transcription factor complex. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16292-16301.	3.3	64
113	Notch signaling as a therapeutic target. Current Opinion in Chemical Biology, 2002, 6, 501-509.	2.8	63
114	Aggressive Langerhans cell histiocytosis following Tâ€ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. American Journal of Hematology, 2008, 83, 116-121.	2.0	63
115	Notch signaling in leukemia. Current Opinion in Hematology, 2001, 8, 237-244.	1.2	62
116	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	3.2	61
117	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature, 2014, 513, 512-516.	13.7	60
118	Targeting the Notch Pathway: Twists and Turns on the Road to Rational Therapeutics. Journal of Clinical Oncology, 2012, 30, 2418-2420.	0.8	59
119	DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. Journal of Clinical Investigation, 2019, 129, 5005-5019.	3.9	59
120	Mutational and Energetic Studies of Notch1 Transcription Complexes. Journal of Molecular Biology, 2008, 376, 131-140.	2.0	54
121	Insights into Autoregulation of Notch3 from Structural and Functional Studies of Its Negative Regulatory Region. Structure, 2015, 23, 1227-1235.	1.6	54
122	Network analysis of gene essentiality in functional genomics experiments. Genome Biology, 2015, 16, 239.	3.8	50
123	In Brief: Notch signalling in health and disease. Journal of Pathology, 2014, 232, 1-3.	2.1	47
124	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
125	Targeted inhibition of CD47-SIRPÎ± requires Fc-FcÎ³R interactions to maximize activity in T-cell lymphomas. Blood, 2019, 134, 1430-1440.	0.6	45
126	Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2343-2353.	1.1	43

#	Article	IF	Citations
127	Canonical Notch Signaling Is Dispensable for the Maintenance of Adult Hematopoietic Stem Cells.. Blood, 2005, 106, 267-267.	0.6	42
128	Detection of activatingMAP2K1mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leukemia and Lymphoma, 2017, 58, 233-236.	0.6	39
129	Genome-wide identification and characterization of Notch transcription complexâ€“binding sequence-paired sites in leukemia cells. Science Signaling, 2017, 10, .	1.6	39
130	Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and Tâ€ALL like mutations. American Journal of Hematology, 2018, 93, 1358-1367.	2.0	39
131	Deregulated NOTCH Signaling in Acute T-Cell Lymphoblastic Leukemia/Lymphoma: New Insights, Questions, and Opportunities. International Journal of Hematology, 2005, 82, 295-301.	0.7	37
132	Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genetics, 2019, 15, e1008039.	1.5	37
133	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discovery, 2019, 9, 944-961.	7.7	36
134	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480.	0.6	35
135	High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood, 2016, 128, 2229-2240.	0.6	33
136	Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma. American Journal of Surgical Pathology, 2017, 41, 1473-1482.	2.1	32
137	The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. PLoS ONE, 2017, 12, e0185762.	1.1	32
138	Angiopoietin-like proteins stimulate HSPC development through interaction with notch receptor signaling. ELife, 2015, 4, .	2.8	30
139	Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilinâ€associated Î³â€Secretase Activity. Annals of the New York Academy of Sciences, 2000, 920, 223-226.	1.8	29
140	A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors. Scientific Reports, 2015, 5, 11012.	1.6	29
141	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2025-2037.	3.3	27
142	Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE, 2019, 14, e0216810.	1.1	20
143	Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling. Science Signaling, 2019, 12, .	1.6	19
144	Notch signaling in cancer: Complexity and challenges on the path to clinical translation. Seminars in Cancer Biology, 2022, 85, 95-106.	4.3	17

#	Article	IF	Citations
145	Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. Blood Advances, 2021, 5, 71-83.	2.5	17
146	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	0.6	15
147	Transcriptional Regulatory Networks Downstream of NOTCH1 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 740-740.	0.6	15
148	Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. Journal of Physical Education and Sports Management, 2015, 1, a000307.	0.5	13
149	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Advances, 2017, 1, 1786-1789.	2.5	13
150	IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. ELife, 2020, 9, .	2.8	13
151	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	2.9	12
152	NFÎºB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFÎºB Target Genes.. Blood, 2004, 104, 243-243.	0.6	11
153	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood, 2021, 138, 2435-2440.	0.6	10
154	Activation of Notch and Myc Signaling via B-cellâ€“Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.4	10
155	suz12 inactivation in p53 and nf1 deficient zebrafish accelerates the onset of MPNSTs and expands the spectrum of tumor types to include adenocarcinoma, leukemia, and soft tissue sarcoma. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	9
156	Notch Ankyrin Repeat Domain Variation Influences Leukemogenesis and Myc Transactivation. PLoS ONE, 2011, 6, e25645.	1.1	9
157	An asymptomatic 61â€yearâ€old man with BCRâ€ABLâ€positive bone marrow following autologous transplantation for multiple myeloma. American Journal of Hematology, 2010, 85, 944-946.	2.0	8
158	A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. International Journal of Surgical Pathology, 2020, 28, 128-137.	0.4	8
159	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	2.5	8
160	A germinal centerâ€“associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Advances, 2022, 6, 2388-2402.	2.5	8
161	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood, 2016, 128, 753-753.	0.6	7
162	Complexity Made Simple in Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 5291-5293.	3.2	6

#	Article	IF	Citations
163	Lymphocyte-Predominant Hodgkin's Disease: How Little Therapy Is Enough?. Journal of Clinical Oncology, 1999, 17, 744-744.	0.8	5
164	Dicing up T-ALL. Blood, 2015, 126, 929-930.	0.6	5
165	MAML1-Dependent Notch-Responsive Genes Exhibit Differing Cofactor Requirements for Transcriptional Activation. Molecular and Cellular Biology, 2020, 40, .	1.1	5
166	Deletion-Based Mechanisms of Notch1 Activation In T-ALL: Key Roles for RAG Recombinase and A Conserved Internal Translational Start Site In Notch1.. Blood, 2010, 116, 3367-3367.	0.6	5
167	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. Blood, 2015, 126, 817-817.	0.6	5
168	IGH rearrangement in myeloid neoplasms. Haematologica, 2020, 105, e315-e317.	1.7	4
169	Tribbles Homolog 2 (Trib2) Inactivates C/EBPalpha and Causes Acute Myelogenous Leukemia.. Blood, 2006, 108, 776-776.	0.6	4
170	Gain-of-Function NOTCH1 Mutations Occur Frequently in Human T Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 4-4.	0.6	4
171	Notch targeting 2.0. Blood, 2009, 113, 6044-6045.	0.6	3
172	Modular Domains within a Super Enhancer Determine Drug Resistance in Leukemia. Blood, 2015, 126, 44-44.	0.6	3
173	Two-Year Experience of Performing a Next-Generation-Sequencing Based Panel Test in an Academic Medical Center and Its Clinical Impact. Blood, 2016, 128, 1707-1707.	0.6	3
174	Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering. Blood, 2016, 128, 741-741.	0.6	3
175	Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. JCO Precision Oncology, 2022, , .	1.5	3
176	Activating Notch1 Mutations in Mouse Models of T-ALL.. Blood, 2005, 106, 2609-2609.	0.6	2
177	Collaboration Between RUNX and NOTCH Pathways in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1279-1279.	0.6	2
178	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. Blood, 2012, 120, 3558-3558.	0.6	2
179	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. Blood, 2015, 126, 3252-3252.	0.6	2
180	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. Blood, 2016, 128, 457-457.	0.6	2

#	Article	IF	Citations
181	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. Human Pathology: Case Reports, 2018, 11, 19-20.	0.2	1
182	Concomitant classic Hodgkin lymphoma and schistosomiasis. American Journal of Hematology, 2019, 94, 840-841.	2.0	1
183	A Novel SEC22B-NOTCH2 Fusion in Chronic Lymphocytic Leukemia. Human Pathology: Case Reports, 2020, 21, 200408.	0.2	1
184	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.. Blood, 2004, 104, 25-25.	0.6	1
185	Hodgkinâ€™s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.. Blood, 2006, 108, 469-469.	0.6	1
186	Sporadic Notch1 Mutations Found in Human T-ALL Drive T Cell Development but Not Leukemogenesis in Murine Models: Implications for Pathogenesis and gamma-Secretase Inhibitor (GSI) Therapy.. Blood, 2006, 108, 707-707.	0.6	1
187	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. Blood, 2016, 128, 3015-3015.	0.6	1
188	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. Blood, 2016, 128, 4045-4045.	0.6	1
189	A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 89-89.	0.6	1
190	Functional Analysis of Leukemia-Associated Mutations Involving the Heterodimerization Domain of NOTCH1.. Blood, 2005, 106, 843-843.	0.6	1
191	Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative. Blood, 2014, 124, 2158-2158.	0.6	1
192	Efficient Inhibition of Notch3 and Notch4 Family Members In Vivo by a Dominant Negative Mutant of Mastermind.. Blood, 2004, 104, 1617-1617.	0.6	0
193	Intrathymic and Extrathymic Notch-Dependent T Lineage Checkpoints during Normal Development and after Bone Marrow Transplantation.. Blood, 2004, 104, 1190-1190.	0.6	0
194	Identification of a C-Terminal Negative Regulatory Sequence in NOTCH1 That Influences Signal Strength and Leukemogenic Activity.. Blood, 2005, 106, 535-535.	0.6	0
195	NOTCH1-Induced T-Cell Leukemia in Transgenic Zebrafish.. Blood, 2006, 108, 1825-1825.	0.6	0
196	Notch Signaling Induces Megakaryocytic Cell Fate.. Blood, 2007, 110, 200-200.	0.6	0
197	Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. Blood, 2008, 112, 200-200.	0.6	0
198	High-Level Expression of Mastermind-Like 2 (MAML2) Contributes to Aberrant Activation of the NOTCH Signaling Pathway In Human Lymphomas. Blood, 2010, 116, 2685-2685.	0.6	0

#	Article	IF	Citations
199	Critical Functions for Notch Dimerization In T Cell Transformation.. Blood, 2010, 116, 3647-3647.	0.6	0
200	Genome-Wide Analysis Reveals Conserved and Divergent Features of Notch1/RBPJ Binding in Human and Murine T Lymphoblastic Leukemia Cells. Blood, 2011, 118, 5236-5236.	0.6	0
201	Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. Blood, 2011, 118, 555-555.	0.6	0
202	Genome-Wide Analysis of NOTCH1, ETS Family Factors, and RUNX1 Binding in Human T Lymphoblastic Leukemia Cells Reveals Distinct Regulatory Elements. Blood, 2012, 120, 1277-1277.	0.6	0
203	Defined, Serum-Free Conditions for in Vitro culture of Primary Human T-ALL Blasts. Blood, 2012, 120, 3537-3537.	0.6	0
204	Angiopoietin-Like Proteins Stimulate HSC Development Through Direct Interaction With Notch. Blood, 2013, 122, 463-463.	0.6	0
205	RUNX1 Is Required For Maintenance Of Established T-ALL Blasts. Blood, 2013, 122, 3742-3742.	0.6	0
206	Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones. Blood, 2013, 122, 2677-2677.	0.6	0
207	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0
208	Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma. Blood, 2014, 124, 863-863.	0.6	0
209	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	0.6	0
210	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. Blood, 2016, 128, 919-919.	0.6	0
211	Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2742-2742.	0.6	0
212	Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity. Blood, 2018, 132, 542-542.	0.6	0
213	Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL. Blood, 2019, 134, 3953-3953.	0.6	0
214	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. Blood, 2019, 134, 3948-3948.	0.6	0
215	NOTCH SIGNALING IN CONTEXT: BASIC AND TRANSLATIONAL IMPLICATIONS. Transactions of the American Clinical and Climatological Association, 2020, 131, 147-156.	0.9	0
216	B Cell-Restricted Depletion of Dnmt3a Activates Notch Signaling and Causes Chronic Lymphocytic Leukemia. Blood, 2021, 138, 249-249.	0.6	0